In this third article, we turn to one of the most decisive and controversial components of HTAs:Â economic evidence, which primarily compares the benefits of a treatment with its associated costs.Â
There are different models used across European countries to perform HTAs. These models establish a framework that shapes whether, when, and how much weight the types of evidence (clinical, economic, and others) are given.Â
In our previous article about Health Technology Assessments (HTAs), we explained what HTAs are and why they matter. If you haven’t had the chance to read it, we suggest you take a look and then come back here, since there is valuable information there too.
In today’s article, we want to take a deeper dive into the topic of HTAs and their importance for the HD community.
Health technologies include medications, devices, and systems designed to address health problems, improve health outcomes, and enhance the quality of care.
For HD, health technologies include potential therapies that, if developed, could profoundly impact patients’ lives.
But, in case a therapy is developed, how do governments decide which health technologies are worth adopting? This is where Health Technology Assessments (HTAs) come in.
Our HTA project is supported by:
